Neurimmune turns future royalties into $425m pipeline cash

Why it matters: The deal allows Neurimmune to raise substantial non-dilutive funding without issuing shares. Since the responsibility for cliramitug’s costly late-stage development already sits with AstraZeneca, this money can directly be invested in the development of earlier-stage assets.

By the numbers: Royalty Pharma will pay Neurimmune $125 million upfront and another $125 million in the first quarter of 2027. A further $175 million is tied to undisclosed clinical and regulatory milestones.

• In return, Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune said it will retain a “substantial” portion of its original royalty and milestone rights.

Backstory: Neurimmune licensed cliramitug to AstraZeneca’s rare disease unit Alexion in 2022.

• That agreement included $30 million upfront, up to $730 million in potential milestones and royalties in the low-to-mid teens. AstraZeneca is responsible for further clinical development, manufacturing and commercialization.

Zoom in: Cliramitug is being tested in the Phase 3 DepleTTR-CM trial in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

• ATTR-CM is a progressive and often underdiagnosed heart disease caused by misfolded transthyretin proteins accumulating in the heart. The deposits thicken and stiffen the heart muscle, gradually reducing its ability to pump blood and leading to heart failure. The disease can be hereditary or develop with age, particularly in older men.

• Most current treatments try to prevent further damage. TTR stabilisers such as tafamidis and acoramidis stop the protein from breaking apart and forming new deposits, while RNA-targeted therapies reduce its production in the liver.

• Cliramitug takes a different approach: the antibody is designed to clear amyloid that has already accumulated in the heart. No amyloid-depleting treatment is currently approved for ATTR-CM.

Catch up quick: The distinction has become more relevant after AstraZeneca and Ionis’ eplontersen recently failed to significantly reduce cardiovascular deaths and clinical events when added to modern standard care in a Phase 3 trial.

The bigger picture: Royalty Pharma has become an increasingly influential source of capital as difficult public markets have pushed biotech companies to look beyond conventional fundraising.

• The New York-based company agreed this year to provide up to $500 million to support Johnson & Johnson’s development of an autoimmune antibody and up to $500 million for Teva’s experimental vitiligo treatment. In both cases, Royalty Pharma’s eventual return is linked to the programmes’ commercial success.
• Its portfolio generated $3.25 billion in receipts in 2025, up 16% from the previous year, illustrating the scale pharmaceutical royalty financing has reached.

• The Neurimmune deal deepens Royalty Pharma’s financial exposure to the fast-growing ATTR-CM market. In November 2025, it paid Blackstone Life Sciences $310 million for a 1% royalty on worldwide sales of Alnylam’s Amvuttra through March 2035. The RNA interference drug was approved in the U.S. for ATTR-CM in 2025 and works by reducing the liver’s production of transthyretin.

How it works: Royalty Pharma effectively converts uncertain future drug sales into cash today. The company buys existing royalty streams or finances drug development in exchange for a share of future sales. For biotechs, that can provide capital without the dilution of an equity financing. For Royalty Pharma, the return depends on the drug reaching the market and generating enough sales to exceed its investment.

What’s next: Neurimmune’s CEO Roger Nitsch said the proceeds would fund the company’s internal R&D programmes.

• Its pipeline includes AP-101, a Phase 2 antibody targeting misfolded SOD1 in amyotrophic lateral sclerosis; NG004 for spinal cord injury; NI009 for AL amyloidosis; and earlier-stage programmes targeting neurodegenerative and protein aggregation diseases. Several of these assets are also being developed with partners, including AstraZeneca, Ono Pharmaceutical, AL-S Pharma and NovaGo Therapeutics.